Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

MSQ rules out deal with Martin Sorrell's S4 Capital

(Sharecast News) - MSQ Partners has poured cold water over the idea of a potential merger with Martin Sorrell's S4 Capital. In a brief statement on Thursday, the company said it had been "surprised" by the speculation and recent announcement regarding a potential merger with S4 Capital.

S4 announced on Monday that it had received a proposal from MSQ, a creative and technology agency owned by One Equity Partners, about a possible combination.

Responding to a Sky News report, S4 said discussions were at a "very preliminary" stage and that there could be no certainty that a transaction would be forthcoming.

If agreed, it said, the possible combination would be structured as an acquisition of MSQ by S4 Capital and not an offer under the takeover code for S4 Capital by MSQ.

But MSQ said on Thursday that its board of directors has not been involved in discussions regarding, or considered any proposal for S4 Capital.

"While speculative informal conversations form part of the investor community and MSQ understands that such discussions may have taken place between representatives of One Equity Partners (OEP), MSQ's majority shareholder, and S4 Capital, for the avoidance of doubt, neither OEP nor MSQ intend to pursue further discussions regarding the rumoured transaction," MSQ said.

"MSQ remains focused on and confident in its primarily organic growth strategy, which has delivered consistent revenue and EBITDA growth over a 15 year period and two of the most successful private equity exits in the marcomms sector over recent years," it added.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.